Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31415
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cambron, Melissa | - |
dc.contributor.author | Mostert, Jop | - |
dc.contributor.author | D'Hooghe, Marie | - |
dc.contributor.author | Nagels, Guy | - |
dc.contributor.author | Willkens, Barbara | - |
dc.contributor.author | Debruyne, Jan | - |
dc.contributor.author | Algoed, Luc | - |
dc.contributor.author | Verhagen, Winn | - |
dc.contributor.author | Hupperts, Raymond | - |
dc.contributor.author | Heersema, Dorothea | - |
dc.contributor.author | De Keyser, Jacques | - |
dc.contributor.author | De Groot, Liesbeth | - |
dc.contributor.author | Foselle, Erwin | - |
dc.contributor.author | Guillaume, Daniel | - |
dc.contributor.author | Merckx, Henri | - |
dc.contributor.author | Vanopdenbosch, Ludo | - |
dc.contributor.author | Vokaer, Mathieu | - |
dc.contributor.author | DE KLIPPEL, Nina | - |
dc.contributor.author | Nuytten, Dirk | - |
dc.contributor.author | Van Remoortel, Ann | - |
dc.contributor.author | Symons, Anoek | - |
dc.contributor.author | D'haeseleer, Miguel | - |
dc.contributor.author | Bissay, Veronique | - |
dc.contributor.author | Van Merhaegen-Wieleman, Annick | - |
dc.contributor.author | Van Lint, Michel | - |
dc.contributor.author | Michiels, Veronique | - |
dc.contributor.author | Haentjens, Patrick | - |
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Tillemans, Bart | - |
dc.contributor.author | Van Hecke, Wim | - |
dc.contributor.author | Hengstman, Gerald | - |
dc.date.accessioned | 2020-07-06T10:23:19Z | - |
dc.date.available | 2020-07-06T10:23:19Z | - |
dc.date.issued | 2019 | - |
dc.date.submitted | 2020-07-06T10:19:33Z | - |
dc.identifier.citation | Multiple sclerosis, 25 (13) , p. 1728 -1735 | - |
dc.identifier.uri | http://hdl.handle.net/1942/31415 | - |
dc.description.abstract | Background: Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS). Objective: To determine whether fluoxetine slows accumulation of disability in progressive MS. Methods: In a double-blind multicenter phase 2 trial, patients with primary or secondary progressive MS were randomized to fluoxetine 40 mg/day or placebo for a period of 108 weeks. Clinical assessments were performed every 12 weeks by trained study nurses who visited the patients at their home. The primary outcome was the time to a 12-week confirmed 20% increase in the Timed 25 Foot Walk or 9-Hole Peg test. Secondary outcomes included the Hauser ambulation index, cognitive tests, fatigue, and brain magnetic resonance imaging (MRI). Results: In the efficacy analysis, 69 patients received fluoxetine and 68 patients received placebo. Using the log-rank test (p = 0.258) and Cox regression analysis (p = 0.253), we found no significant difference in the primary outcome between the two groups. Due to an unexpected slow rate of progression in the placebo group, there was insufficient statistical power to detect a potential benefit of fluoxetine. We found no differences between the two groups for secondary outcomes. Conclusion: The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS. | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject.other | Multiple sclerosis; progressive multiple sclerosis; clinical trial; | - |
dc.subject.other | fluoxetine; outcome; neuroprotection | - |
dc.title | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1735 | - |
dc.identifier.issue | 13 | - |
dc.identifier.spage | 1728 | - |
dc.identifier.volume | 25 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | De Keyser, J (reprint author), UZ Brussel, Dept Neurol, Laarbeeklaan 101, Brussels, Belgium. | - |
dc.description.notes | jacquesdekeyser@gmail.com | - |
local.publisher.place | 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.class | IncludeIn-ExcludeFrom-List/ExcludeFromFRIS | - |
dc.identifier.doi | 10.1177/1352458519843051 | - |
dc.identifier.isi | WOS:000492996600008 | - |
dc.identifier.eissn | - | |
dc.identifier.eissn | 1477-0970 | - |
local.provider.type | wosris | - |
item.fulltext | With Fulltext | - |
item.fullcitation | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim & Hengstman, Gerald (2019) Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial. In: Multiple sclerosis, 25 (13) , p. 1728 -1735. | - |
item.contributor | Cambron, Melissa | - |
item.contributor | Mostert, Jop | - |
item.contributor | D'Hooghe, Marie | - |
item.contributor | Nagels, Guy | - |
item.contributor | Willkens, Barbara | - |
item.contributor | Debruyne, Jan | - |
item.contributor | Algoed, Luc | - |
item.contributor | Verhagen, Winn | - |
item.contributor | Hupperts, Raymond | - |
item.contributor | Heersema, Dorothea | - |
item.contributor | De Keyser, Jacques | - |
item.contributor | De Groot, Liesbeth | - |
item.contributor | Foselle, Erwin | - |
item.contributor | Guillaume, Daniel | - |
item.contributor | Merckx, Henri | - |
item.contributor | Vanopdenbosch, Ludo | - |
item.contributor | Vokaer, Mathieu | - |
item.contributor | DE KLIPPEL, Nina | - |
item.contributor | Nuytten, Dirk | - |
item.contributor | Van Remoortel, Ann | - |
item.contributor | Symons, Anoek | - |
item.contributor | D'haeseleer, Miguel | - |
item.contributor | Bissay, Veronique | - |
item.contributor | Van Merhaegen-Wieleman, Annick | - |
item.contributor | Van Lint, Michel | - |
item.contributor | Michiels, Veronique | - |
item.contributor | Haentjens, Patrick | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Tillemans, Bart | - |
item.contributor | Van Hecke, Wim | - |
item.contributor | Hengstman, Gerald | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1352458519843051.pdf Restricted Access | Published version | 209.4 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
7
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
22
checked on May 8, 2024
Page view(s)
46
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.